Treatment of Severe Secondary Mitral Regurgitation with Concomitant Coronary Artery Disease Requiring Revascularization

This protocol addresses a specific and clinically important presentation: severe ventricular secondary mitral regurgitation (SMR) occurring alongside ischemic heart disease — in patients whose concomitant coronary artery disease (CAD) itself requires coronary revascularization. The co-existence of these conditions directly shapes the treatment strategy.

Clinical Scenario

Patients present with severe ventricular (secondary) mitral regurgitation and significant coronary artery disease that independently warrants revascularization. This intersection of ischemic heart disease and functional mitral valve pathology raises specific management questions regarding the timing and type of intervention for both conditions.

Key Consideration — Ischemic Heart Disease

In this setting, guidelines address whether and when to treat the mitral valve concurrently with coronary revascularization — with surgical risk profile and coronary anatomy being critical determinants. The approach differs meaningfully from isolated secondary mitral regurgitation without CAD.

Treatment Approach — Partial Overview

Before any mitral valve intervention is considered, guideline-directed medical therapy for heart failure is the recommended foundation — drawing on a combination of established heart failure pharmacological drug classes at maximum tolerated doses. Device-based management may also be part of the overall framework in appropriately selected patients.

The full evidence-based regimen — including specific agents, sequencing, and intervention criteria — is in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehaf194

In patients with severe ischaemic ventricular SMR and concomitant CAD requiring coronary revascularization, MV surgery at the time of CABG is recommended, unless the patient is at high surgical risk and/or the coronary anatomy is suitable for PCI.

In patients with ventricular SMR, GDMT for the treatment of HF is recommended prior to any MV intervention.

View source ↗